NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
Clinical Trials
5 trialsNCT05792410 2023-03-31
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT02983071 2023-02-15
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
G1 Therapeutics, Inc.
Phase 1/2 Unknown
NCT04355520 2020-04-21
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown